Celebrating over ten years supporting vaccine production in Germany
Posted on August 18, 2020 by Helena Graham
This year Zenith Technologies, a Cognizant Company is celebrating over 10 years of working with clients on vaccine production sites in Germany. We recently spoke with the head of the site, Martin Mueller, about the highlights over the past decade and looking ahead to the next ten years.
First Client in Germany
In 2008, Zenith’s first client in Germany initiated a greenfield project to construct a brand-new vaccine production site for a global market. It aimed to serve as the company’s ‘Centre of Excellence’ for modern vaccine production. Zenith teams executed a feasibility study for the project and were selected as the system integrator for the process control system at the new site. Throughout 2009 and 2010, we supported the new facility, performing commissioning and qualification activities with a large team on site, transitioning to offer Managed Services in 2011.
– CIP Optimization
– Process Redesign & Optimization
– Operations Enablement
– Mumps Vaccine Delivery
– Warehouse Extension
The Life Science Industry in Germany
Germany has a flourishing life sciences scene and benefits from a rich network of higher educational institutions and public research organisations. The country is one of Europe’s leading pharmaceutical manufacturing locations and spends an average of three per cent of GDP on R&D annually .
Germany’s pharma manufacturing sector is currently being shaped by key industry trends, including the transition to paperless using Manufacturing Execution Systems (MES) and the growing implementation of single use equipment within pharma production processes.
Looking to the future
As we look ahead to our next 10 years, we plan to expand our offering further to the German market place, and to expand our client base. As such we have a growing requirement for highly skilled German speaking engineers.
In light of recent events around the world with the pandemic, we are also looking to move to a secure remote access environment to support German-based customers 24/7 remotely.
We would like to take this opportunity to congratulate our colleagues in Germany and to thank our clients for their continued partnership. The coming years are set to be extremely exciting as drug developers continue to introduce more technology innovation into their manufacturing processes to continue to produce world leading vaccines.